New drugs: exenatide, pramlintide acetate, and micafungin sodium.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA, USA.
D000682:Amyloid / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy / Q000517:prevention & control; D002986:Clinical Trials as Topic; D004348:Drug Labeling / Q000379:methods; D004356:Drug Storage / Q000379:methods; D054714:Echinocandins; D004935:Esophageal Diseases / Q000188:drug therapy / Q000382:microbiology; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D058228:Islet Amyloid Polypeptide; D055666:Lipopeptides; D008074:Lipoproteins / Q000627:therapeutic use*; D000077551:Micafungin; D010455:Peptides / Q000627:therapeutic use*; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D014688:Venoms / Q000627:therapeutic use*
D000682:Amyloid; D000935:Antifungal Agents; D054714:Echinocandins; D007004:Hypoglycemic Agents; D058228:Islet Amyloid Polypeptide; D055666:Lipopeptides; D008074:Lipoproteins; D010455:Peptides; D010456:Peptides, Cyclic; D014688:Venoms; D000077270:Exenatide; C105254:pramlintide; D000077551:Micafungin